Top Page
Medibank Private
(Sydney:MPL)
Medibank Private (MPL) vs. iShares MSCI Australia ETF (EWA)
Medibank Private Business Overview & Revenue Model
Medibank Private Earnings Call Summary
Medibank Private Financial Statement Overview
| Breakdown | TTM | Jun 2025 | Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 8.76B | 8.56B | 8.02B | 7.40B | 7.09B | 6.98B |
| Gross Profit | 8.76B | 8.56B | 8.02B | 7.40B | 7.10B | 7.03B |
| EBITDA | 694.60M | 750.80M | 806.50M | 520.60M | 635.10M | 715.00M |
| Net Income | 463.40M | 500.80M | 492.50M | 511.10M | 393.90M | 441.20M |
Balance Sheet | ||||||
| Total Assets | 4.26B | 4.70B | 4.69B | 4.39B | 4.55B | 3.92B |
| Cash, Cash Equivalents and Short-Term Investments | 453.30M | 0.00 | 927.90M | 695.10M | 831.30M | 671.70M |
| Total Debt | 481.30M | 209.00M | 218.30M | 55.30M | 76.90M | 93.40M |
| Total Liabilities | 1.92B | 2.36B | 2.38B | 2.30B | 2.61B | 2.02B |
| Stockholders Equity | 2.35B | 2.34B | 2.31B | 2.08B | 1.95B | 1.91B |
Cash Flow | ||||||
| Free Cash Flow | 343.30M | 369.70M | 810.90M | 216.30M | 927.60M | 463.10M |
| Operating Cash Flow | 355.90M | 380.90M | 868.50M | 258.20M | 962.70M | 498.20M |
| Investing Cash Flow | 136.70M | 110.50M | -110.80M | -15.20M | -637.80M | -322.10M |
| Financing Cash Flow | -559.30M | -533.80M | -487.30M | -419.10M | -399.90M | -375.80M |
Medibank Private Technical Analysis
Medibank Private Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
80 Outperform | AU$32.81B | 9.92 | 18.97% | 4.68% | 5.93% | 14.80% | |
72 Outperform | AU$3.12B | 15.62 | 18.51% | 4.17% | 5.90% | 7.22% | |
69 Neutral | $12.06B | 26.02 | 21.28% | 3.73% | 6.37% | 1.73% | |
68 Neutral | $18.00B | 11.42 | 9.92% | 3.81% | 9.73% | 1.22% | |
65 Neutral | $15.84B | 16.04 | 12.51% | 26.88% | -0.54% | 26.37% | |
63 Neutral | AU$15.75B | 14.48 | 19.09% | 3.91% | 8.47% | 54.09% | |
60 Neutral | €3.30B | 15.64 | 11.17% | 2.95% | 10.98% | 23.05% |
Medibank Private Corporate Events
Medibank Private has released a half-year investor presentation for the period ended 31 December 2025, outlining general information on its operations, financial reporting framework and disclosure practices. The document emphasises that the material is a high-level summary to be read alongside formal ASX filings and that figures are in Australian dollars and subject to rounding.
The release stresses extensive disclaimers on forward-looking statements, highlighting that expectations are subject to economic, regulatory and market risks, and may differ materially from actual results. It also clarifies that the presentation does not constitute financial advice or an offer of securities, underscoring the need for investors to seek independent advice and observe jurisdictional restrictions on distribution.
The most recent analyst rating on (AU:MPL) stock is a Hold with a A$5.10 price target. To see the full list of analyst forecasts on Medibank Private stock, see the AU:MPL Stock Forecast page.
Medibank Private reported a solid first-half 2026 result driven by stronger customer engagement, with net resident policyholders up 1.9% to 38,300 over 12 months and non-resident policy units up 0.4%. The group paid $3.5 billion in claims, delivered $130.7 million in customer value and saw 55% of resident policyholders engage with its health and wellbeing services, while its Live Better rewards program surpassed 1 million members.
Group operating profit rose 6.0% to $381.7 million, supported by a 3.5% lift in health insurance profit and a 28.5% increase in Medibank Health segment profit, though underlying NPAT edged down 0.3% to $297.8 million amid lower investment income and ongoing cyber-related costs. The company increased its fully franked interim dividend by 6.4% to 8.3 cents per share and continued to diversify into primary care with the acquisition of Better Medical, reinforcing its strategy to lead a shift toward prevention and early intervention in an Australian health system under growing strain.
The most recent analyst rating on (AU:MPL) stock is a Hold with a A$5.10 price target. To see the full list of analyst forecasts on Medibank Private stock, see the AU:MPL Stock Forecast page.
Medibank Private has declared an ordinary interim dividend of AUD 0.083 per fully paid share for the six-month period ended 31 December 2025. The dividend will trade ex-dividend on 26 February 2026, with a record date of 27 February 2026 and payment scheduled for 18 March 2026, signalling ongoing capital returns to shareholders in line with its regular distribution timetable.
The most recent analyst rating on (AU:MPL) stock is a Hold with a A$5.10 price target. To see the full list of analyst forecasts on Medibank Private stock, see the AU:MPL Stock Forecast page.
Medibank Private has reported its financial results for the half year ended 31 December 2025, showing a 5.5% increase in revenue from ordinary activities to $4.50 billion, driven by 4.4% growth in health insurance revenue and a 32.3% rise in other operating revenue. Despite the top-line growth, profit after tax attributable to equity holders declined 11% to $302.9 million and net tangible assets per share fell to 54.7 cents from 65.3 cents, though the board maintained shareholder returns by declaring a fully franked interim dividend of 8.30 cents per share, payable in March 2026.
The company also noted that a fully franked final dividend of 10.20 cents per share had been paid in October 2025 for the prior half year, underscoring its ongoing capital return policy. The combination of higher revenues but lower profit and reduced net tangible assets per share suggests margin or cost pressures within the business, even as Medibank continues to leverage its health insurance portfolio and related services to support shareholder distributions and maintain its position in the Australian private health insurance market.
The most recent analyst rating on (AU:MPL) stock is a Hold with a A$5.10 price target. To see the full list of analyst forecasts on Medibank Private stock, see the AU:MPL Stock Forecast page.
Medibank has announced the retirement of The Hon Jay Weatherill AO as a non-executive director, effective 31 December 2025, and has lodged a Final Director’s Interest Notice with the ASX in accordance with listing requirements. The filing confirms that Weatherill held no Medibank securities in his own name at the time of ceasing to be a director, indicating no direct equity stake remains tied to his tenure and signalling a clean governance transition for the board and its stakeholders.
The most recent analyst rating on (AU:MPL) stock is a Buy with a A$5.50 price target. To see the full list of analyst forecasts on Medibank Private stock, see the AU:MPL Stock Forecast page.
Medibank Private Limited has notified the ASX of the cessation of 152,254 performance rights (security code MPLAA) as of 31 December 2025, after the conditional rights lapsed because their vesting conditions were not met or became incapable of being satisfied. The lapse of these performance rights effectively reduces the pool of potential future equity issuance under this particular incentive arrangement, which may marginally impact dilution expectations for existing shareholders but does not alter the company’s current issued capital structure.
The most recent analyst rating on (AU:MPL) stock is a Buy with a A$5.50 price target. To see the full list of analyst forecasts on Medibank Private stock, see the AU:MPL Stock Forecast page.
Medibank has announced a change in the recording of director David Koczkar’s interests in company securities, clarifying that while the entities through which his holdings are held have changed, the total number of Medibank securities in which he has a direct and indirect interest remains unchanged from the disclosure lodged on 19 December 2025. The update is a technical adjustment to the register of interests rather than a change in Koczkar’s overall economic exposure to Medibank, and reflects the company’s ongoing compliance with ASX disclosure requirements and corporate governance obligations, with no direct operational or strategic impact indicated for shareholders or other stakeholders.
The most recent analyst rating on (AU:MPL) stock is a Hold with a A$5.05 price target. To see the full list of analyst forecasts on Medibank Private stock, see the AU:MPL Stock Forecast page.
Medibank Private Limited has notified the market of the issue of 3,230,852 unquoted performance rights under its employee incentive scheme. These performance rights, which are not intended to be quoted on the ASX, were issued on 12 December 2025 and reflect the company’s ongoing use of equity-based incentives to align employee remuneration with long-term shareholder value.
The most recent analyst rating on (AU:MPL) stock is a Hold with a A$5.05 price target. To see the full list of analyst forecasts on Medibank Private stock, see the AU:MPL Stock Forecast page.
Medibank Private Limited has announced key dates for the first half of the fiscal year 2026, including the release of its half-year results on February 19, 2026. The company will host a teleconference and webcast briefing for investors and analysts on the same day, led by CEO David Koczkar and CFO Mark Rogers. Additionally, Medibank has scheduled its interim dividend payment dates, with the ex-dividend date set for February 26, 2026, and the payment date on March 18, 2026. These announcements are crucial for stakeholders as they provide insights into the company’s financial performance and shareholder returns.
The most recent analyst rating on (AU:MPL) stock is a Hold with a A$5.05 price target. To see the full list of analyst forecasts on Medibank Private stock, see the AU:MPL Stock Forecast page.
Medibank Private Limited has announced the appointment of Jacqueline Hey and Dr. Lisa McIntyre as non-executive directors, effective from November 19, 2025. This strategic addition to the board is expected to enhance the company’s governance and potentially strengthen its market position, reflecting Medibank’s commitment to robust leadership and strategic oversight.
The most recent analyst rating on (AU:MPL) stock is a Buy with a A$5.84 price target. To see the full list of analyst forecasts on Medibank Private stock, see the AU:MPL Stock Forecast page.
Medibank Private Limited successfully held its 2025 Annual General Meeting, where all resolutions from 2 to 7 were passed as ordinary resolutions by poll. The re-election of directors Kathryn Fagg AC and Peter Everingham, along with the election of Dr. Lisa McIntyre and Jacqueline Hey, were approved, reflecting strong shareholder support. Additionally, the adoption of the remuneration report and the grant of performance rights to the CEO were also sanctioned, indicating confidence in the company’s leadership and strategic direction.
The most recent analyst rating on (AU:MPL) stock is a Buy with a A$5.84 price target. To see the full list of analyst forecasts on Medibank Private stock, see the AU:MPL Stock Forecast page.